BioSpace News Archive

Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced an agreement granting Elanco Animal Health Incorporated exclusive global rights to KIND-030, a monoclonal antibody targeting canine parvovirus (CPV).

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced that Natasha A. Hernday has joined Alpine’s Board of Directors.

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of BAVENCIO®

ESCAPE Bio Inc., a clinical stage company developing novel, precisely targeted therapeutics for genetic neurodegenerative diseases, announced that Edward Owens and Scott Morrison have been appointed to the Board of Directors.

Envision Healthcare, one of the country’s leading medical groups, announced today new additions and transitions within its leadership team. “As a leading national medical group, we are proud to build a team of talented, innovative individuals who make our business better,” said President and Chief Executive Officer Jim Rechtin. “Our senior leaders are focused on building a strong and nimble organization that can ta

HOOKIPA Pharma Inc. (Nasdaq: HOOK), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the closing of its previously announced underwritten public offering of an aggregate of 3,910,000 shares of its common stock and 2,978 shares of its Series A convertible preferred stock (the “Offering”). The public offering price of each share of common stock is $11.75 and the pub

Ziopharm Oncology, Inc., issued a statement in connection with the consent solicitation initiated by WaterMill Asset Management Corp., Mr. Robert W. Postma and certain other individuals following the delay of the original December 11 deadline set by WaterMill for Ziopharm shareholders to deliver written consents in support of the Consent Solicitation.

The leaders of 18 pharmacy organizations issued the following statement following the Food and Drug Administration’s approval of the first Emergency use Authorization for the COVID-19 vaccine.